Expert Interview
Discussing Mirati's MRTX1719, a MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality, in patients with MTAP deleted cancer
Ticker(s): MRTX, TNGXInstitution: Brigham and Women's Hospital
- Medical Oncologist and Professor of Medicine at Harvard Medical School, and Senior Physician at Brigham and Women’s Hospital/Dana-Farber Cancer Institute
- Manages 10+ patients with mesothelioma
- Research interests are: personalized/targeted treatment of cancers according to their mutations, targeting the mTOR pathway in cancer, and mesothelioma therapeutic development and treatment
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
